Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Veracyte (VCYT) Other Operating Expenses (2016 - 2025)

Veracyte's Other Operating Expenses history spans 14 years, with the latest figure at $26.6 million for Q4 2025.

  • For Q4 2025, Other Operating Expenses fell 6.39% year-over-year to $26.6 million; the TTM value through Dec 2025 reached $123.2 million, up 20.63%, while the annual FY2025 figure was $123.2 million, 20.63% up from the prior year.
  • Other Operating Expenses for Q4 2025 was $26.6 million at Veracyte, up from $25.1 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $59.8 million in Q3 2023 and bottomed at -$61.3 million in Q4 2022.
  • The 5-year median for Other Operating Expenses is $29.4 million (2021), against an average of $33.5 million.
  • The largest annual shift saw Other Operating Expenses plummeted 221.25% in 2022 before it soared 143.7% in 2023.
  • A 5-year view of Other Operating Expenses shows it stood at $50.6 million in 2021, then tumbled by 221.25% to -$61.3 million in 2022, then skyrocketed by 143.7% to $26.8 million in 2023, then rose by 5.9% to $28.4 million in 2024, then fell by 6.39% to $26.6 million in 2025.
  • Per Business Quant, the three most recent readings for VCYT's Other Operating Expenses are $26.6 million (Q4 2025), $25.1 million (Q3 2025), and $46.4 million (Q2 2025).